Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental lymphoma drug IPH6501 tested in early trial – but study halted

NCT ID NCT06088654

Disease control Sponsor: Innate Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. The study was terminated early, so results are limited and it is unclear if the drug will move forward.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IPH6501 (an experimental drug that targets CD20 on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with certain types of Non-Hodgkin lymphoma that have not responded to other therapies.
What could go wrong
This is a very early (first-in-human) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

23 people

The number who actually took part.

Started

Mar 2024

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion criteria * Patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin's lymphoma (NHL) including the following types defined by WHO 2016: Diffuse Large B Cell Lymphoma (DLBCL); high grade; thymic; Follicular Lymphoma (FL); Mantle cell lymphoma (MCL); Marginal zone lymphoma (MZL) * Relapsed, progressive and/or refractory disease without established alternative therapy * Must have received at least 2 prior systemic therapies including at a minimum anti-CD20 antibody therapy (e.g., rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Adequate organ and hematological function * Able to provide a fresh biopsy from a safely accessible site (or historical biopsy), per investigator determination. Main Exclusion Criteria * Patients with another invasive malignancy in the last 2 years * Prior chemotherapy, immunotherapy or other anti-cancer therapy within less than 4 weeks before study drug administration. * Autologous stem cell transplant or treatment with CAR-T (Chimeric Antigen Receptor T-Cell) cell therapy within 100 days prior to first dose of study drug * Subjects with brain or subdural metastases are not eligible, nor those with history of central nervous system (CNS) lymphoma * Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. * Known history of infection with human immunodeficiency virus (HIV) or hepatitis B or C * Major surgery within 4 weeks before the first dose of study drug * Comorbidities including diabetes, cardiovascular diseases, immunodeficiencies/autoimmune condition * Pregnant / breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-Hodgkin lymphoma

Contacts and locations

Locations

  • Austin Health

    Heidelberg, Australia

  • Cedars Sinai

    Los Angeles, California, 90048, United States

  • Centre Hospitalier Regional Universitaire de Lille

    Lille, France

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France

  • City of Hope

    Duarte, California, 91010, United States

  • Hospices Civils de Lyon

    Lyon, 69002, France

  • Hôpital de la Coception

    Marseille, 13005, France

  • Icahn School Of Medicine At Mount Sinai

    New York, New York, 10029, United States

  • Institute Bergonie

    Bordeaux, France

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Monash Health

    Clayton, Victoria, 3168, Australia

  • Peninsula Private Hospital

    Frankston, Victoria, 3910, Australia

  • Siteman Cancer Center

    St Louis, Missouri, 63110, United States

  • Wollongong Private Hospital

    Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.